Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ruxolitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 15/20 | 1.00 |
| ▸ | JAK1 known ✓ | P23458 | 14/20 | 1.00 |
| ▸ | JAK3 known ✓ | P52333 | 6/20 | 1.00 |
| ▸ | TYK2 known ✓ | P29597 | 3/20 | 1.00 |
| ▸ | ABL1 | P00519 | 3/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 1.00 |
| ▸ | PAK4 | O96013 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | LTK | P29376 | 2/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 1.00 |
| ▸ | CLK2 | P49760 | 2/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 2/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 2/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 2/20 | 1.00 |
| ▸ | IKBKE | Q14164 | 2/20 | 1.00 |
| ▸ | NTRK3 | Q16288 | 2/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 2/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 1.00 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 1.00 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ruxolitinib SCHEMBL29349794 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL29677353 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL26927161 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL101279 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL31247553 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL171319 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL26927158 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL29808249 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| SCHEMBL99371 | 0.99 | JAK2 (0.98) | JAK2JAK1JAK3ABL1TYK2 | |
| SCHEMBL99245 | 0.99 | JAK2 (0.98) | JAK2JAK1JAK3ABL1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340848-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4602148-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | Peking University (CN) | 2025-08-20 | — | — | EP | claimed |
| US-20240384233-A1 | Method for Producing Cardiomyocytes by Means of Reprogramming | PLASTECH PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-11-21 | — | — | US | claimed |
| WO-2024184926-A1 | PROCESS FOR PREPARATION OF CHIRAL RUXOLITINIB AND SALTS THEREOF | AARTI PHARMALABS LIMITED (IN) | 2024-09-12 | — | — | WO | claimed |
| WO-2024078119-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2024-04-18 | — | — | WO | claimed |
| US-11931412-B2 | JAK1 inhibitors and uses thereof | WASHINGTON UNIVERSITY (US) | 2024-03-19 | — | — | US | claimed |
| US-20230190736-A1 | SMALL MOLECULE THERAPEUTICS FOR THE TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-22 | — | — | US | claimed |
| CN-116249768-A | Method for producing cardiomyocytes by reprogramming | 南京昕瑞再生医药科技有限公司 | 2023-06-09 | — | — | CN | claimed |
| US-20220307034-A1 | INHIBITING APE2 EXPRESSION IN A SUBJECT TREATED WITH A DRUG AGENT THAT CAUSES INCREASED APE2 EXPRESSION | THE CLEVELAND CLINIC FOUNDATION | 2022-09-29 | — | — | US | claimed |
| US-20220235327-A1 | PANCREATIC DIFFERENTIATION | VERTEX PHARMACEUTICALS INCORPORATED | 2022-07-28 | — | — | US | claimed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | claimed |
| WO-2022022624-A1 | METHOD FOR PRODUCING CARDIOMYOCYTES BY MEANS OF REPROGRAMMING | 南京昕瑞再生医药科技有限公司 | 2022-02-03 | — | — | WO | claimed |
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2020-10-29 | — | — | US | claimed |
| EP-3184526-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2018-10-03 | — | — | EP | claimed |
| EP-3184526-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2017-06-28 | — | — | EP | claimed |
| US-9662335-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-05-30 | — | — | US | claimed |
| US-20160272648-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2016-09-22 | — | — | US | claimed |
| CN-103214484-B | Pyrrolo-[2,3-b] pyridine replaced as the heteroaryl of Janus inhibitors of kinases and pyrrolo-[2,3-b] pyrimidine | 因塞特控股公司 | 2016-07-06 | — | — | CN | claimed |
| CN-103214483-B | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORP | 2014-12-17 | — | — | CN | claimed |
| US-7598257-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2009-10-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
| US-11931412-B2 | JAK1 inhibitors and uses thereof | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885JAK3 2/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
| US-20160272648-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.